PSMC5 and colorectal carcinoma: Moreover, expression of PSMC5 was shown to be related with response to ICB therapy in other cancers including lung cancer, melanoma, and urothelial cancer, which suggested that PSMC5 might be a potential marker or a target for ICB therapy in CRC patients.